No offense, but you badly mis-comprehended what you read. The South Korean study on which the article is founded studied 285 subjects. It's stated in the second sentence of the article.
The n=7 study you're stuck on is referenced in passing in the middle of the article. Those 7 people were tested 9-17 years later for presence of antibodies after having SARS infections. So they found 7 people to participate who had SARS infection 1-2 decades earlier. Not shocked.
And what are these sunshine pumping articles with "incredibly low sample size" you are referencing? You're using plural, but point to just one you're talking about so I can respond in kind.
And to be clear, I am advocating for specific studies to examine the potential benefit of very early intervention of HCQ to inhibit Covid from taking hold. There are trials underway, but even the just announced NIH study may only glancingly touch early intervention, instead incorporating mild cases, not necessarily very early stage infection.
While I don't support mass use of HCQ without better evidence, the discourse has been badly perverted in the US and may create too big an obstacle to overcome in the event studies demonstrate benefit with defined parameters for a safe and effective application. I do think individual states and health care providers with informed consent from patients should be able to apply it now for off label use. I would not give it to complicated illness, signs of acute vasculitis, or those with cardiovascular disease. Best case is it saves lives and reduces transmission. Ideal worst case is that it is applied safely by a knowledgable provider even if no measurable benefit is observed. If diagnosed with Covid, I would be a consenting patient to receive it with zinc today, ASAP, but that's only my personal choice.
Edit: I didn't read the above posts already catching your error.